RJA
TGTX icon

Raymond James & Associates’s TG Therapeutics TGTX Stock Holding History

Raymond James & Associates’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.98M Buy
170,160
+44,972
+36% +$982K ﹤0.01% 1811
2024
Q2 		$2.23M Sell
125,188
-2,029
-2% -$32.4K ﹤0.01% 2095
2024
Q1 		$1.93M Buy
127,217
+775
+0.6% +$12.3K ﹤0.01% 2176
2023
Q4 		$2.16M Sell
126,442
-23,748
-16% -$276K ﹤0.01% 2054
2023
Q3 		$1.26M Buy
150,190
+4,176
+3% +$58.2K ﹤0.01% 2310
2023
Q2 		$3.63M Sell
146,014
-22,829
-14% -$590K ﹤0.01% 1697
2023
Q1 		$2.54M Sell
168,843
-13,370
-7% -$203K ﹤0.01% 1894
2022
Q4 		$2.16M Sell
182,213
-11,925
-6% -$86.5K ﹤0.01% 1948
2022
Q3 		$1.15M Buy
194,138
+17,494
+10% +$115K ﹤0.01% 2308
2022
Q2 		$751K Buy
176,644
+10,650
+6% +$66.5K ﹤0.01% 2640
2022
Q1 		$1.58M Buy
165,994
+6,860
+4% +$79.4K ﹤0.01% 2294
2021
Q4 		$3.02M Sell
159,134
-20,571
-11% -$534K ﹤0.01% 1879
2021
Q3 		$5.98M Sell
179,705
-15,562
-8% -$481K 0.01% 1383
2021
Q2 		$7.57M Sell
195,267
-9,725
-5% -$382K 0.01% 1222
2021
Q1 		$9.88M Sell
204,992
-1,829
-0.9% -$87.9K 0.01% 1043
2020
Q4 		$10.8M Sell
206,821
-9,274
-4% -$313K 0.01% 911
2020
Q3 		$5.78M Sell
216,095
-23,387
-10% -$538K 0.01% 1143
2020
Q2 		$4.67M Sell
239,482
-34,085
-12% -$549K 0.01% 1227
2020
Q1 		$2.69M Sell
273,567
-48,065
-15% -$607K ﹤0.01% 1407
2019
Q4 		$3.57M Sell
321,632
-11,017
-3% -$83.8K ﹤0.01% 1472
2019
Q3 		$1.87M Buy
332,649
+19,629
+6% +$137K ﹤0.01% 1815
2019
Q2 		$2.71M Sell
313,020
-68,417
-18% -$517K ﹤0.01% 1611
2019
Q1 		$3.07M Buy
381,437
+51,418
+16% +$278K ﹤0.01% 1499
2018
Q4 		$1.35M Buy
330,019
+96,385
+41% +$479K ﹤0.01% 1899
2018
Q3 		$1.31M Buy
233,634
+125,352
+116% +$1.43M ﹤0.01% 2071
2018
Q2 		$1.42M Sell
108,282
-117,735
-52% -$1.62M ﹤0.01% 1982
2018
Q1 		$3.21M Buy
226,017
+14,422
+7% +$184K 0.01% 1409
2017
Q4 		$1.74M Buy
211,595
+122,400
+137% +$1.07M ﹤0.01% 1771
2017
Q3 		$1.06M Buy
89,195
+5,687
+7% +$64.8K ﹤0.01% 2058
2017
Q2 		$839K Sell
83,508
-22,254
-21% -$249K ﹤0.01% 2137
2017
Q1 		$1.23M Buy
105,762
+53,442
+102% +$384K ﹤0.01% 1837
2016
Q4 		$243K Buy
52,320
+28,708
+122% +$168K ﹤0.01% 2779
2016
Q3 		$183K Buy
23,612
+8,212
+53% +$52.8K ﹤0.01% 2875
2016
Q2 		$93K Buy
15,400
+1,681
+12% +$13.7K ﹤0.01% 2816
2016
Q1 		$117K Buy
+13,719
New +$120K ﹤0.01% 2688
2015
Q3 		– Sell
-17,413
Closed -$289K – 2381
2015
Q2 		$289K Sell
17,413
-1,662
-9% -$26.3K ﹤0.01% 2290
2015
Q1 		$295K Buy
+19,075
New +$289K ﹤0.01% 2223

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's TGTX Position: Q3 2024 in Review

Raymond James & Associates increased its TG Therapeutics (TGTX) stake by 36% in Q3 2024, buying an estimated $982K and bringing the position to 170,160 shares worth $3.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1811.

Raymond James & Associates first reported a position in TGTX in Q1 2015 and has held it in 37 quarters since. The position peaked at $10.8M in Q4 2020. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • Raymond James & Associates held 170,160 shares of TG Therapeutics worth $3.98M as of Q3 2024.
  • Raymond James & Associates bought 44,972 TG Therapeutics shares in Q3 2024, an estimated $982K.
  • TG Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1811 holding.
  • Raymond James & Associates first reported a position in TG Therapeutics in Q1 2015 and has held it in 37 quarters since.
  • Raymond James & Associates's TG Therapeutics position peaked at $10.8M in Q4 2020.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.